Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges

doi:10.3748/wjg.v31.i15.104901

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 15

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (0)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-1)

Tables (1-2)

Sum=0

Apr 21, 2025 (publication date) through Apr 18, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Gastroenterol. Apr 21, 2025; 31(15): 104901
Published online Apr 21, 2025. doi: 10.3748/wjg.v31.i15.104901

Conversion treatment for advanced intrahepatic cholangiocarcinoma: Opportunities and challenges

Jun-Jie Liu, Mi Zhou, Tong Yuan, Zhi-Yong Huang, Zun-Yi Zhang

Jun-Jie Liu, Mi Zhou, Tong Yuan, Zhi-Yong Huang, Zun-Yi Zhang, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China

Co-corresponding authors: Zhi-Yong Huang and Zun-Yi Zhang.

Author contributions: Huang ZY and Zhang ZY conceived the overall concept and framework of the manuscript; Liu JJ contributed to writing, editing, illustrating, and reviewing the literature; Zhou M and Yuan T participated in the discussion and design of the manuscript. All authors have read and approved the final version. Huang ZY and Zhang ZY contributed equally to this study and are recognized as co-corresponding authors.

Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.

Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Corresponding author: Zun-Yi Zhang, MD, Associate Professor, Hepatic Surgery Center, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, Hubei Province, China. zunyizhangtjmu@163.com

Received: January 5, 2025
Revised: February 22, 2025
Accepted: March 26, 2025
Published online: April 21, 2025
Processing time: 102 Days and 22.3 Hours

Core Tip

Core Tip: The conversion treatment for unresectable intrahepatic cholangiocarcinoma (ICC) can reduce tumor burden and enhance the likelihood of surgical resection. Chemotherapy is still the base treatment for advanced ICC. However, locoregional therapies and systemic therapies are promising treatment strategies for advanced ICC, aiming to enhance tumor response and improve patient outcomes. Achieving an adequate future liver remnant is crucial to prevent posthepatectomy liver failure; techniques are being investigated to enhance future liver remnant and improve outcomes in patients with advanced ICC.